Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-23

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study the investigators propose to perform a Phase II Clinical Trial which seeks to evaluate the safety of cell therapy as a new treatment for patients who suffer from acute non-arteritic anterior ischemic optic neuropathy (NAION). If it is successful, a later study to assess efficacy will be performed.

This disease has an age-adjusted incidence rate of 10/100.000, and in many cases it results in blindness. Currently, there is no available treatment and second eye involvement occurs in approximately 15-25% of the cases.

All this background originates a particularly dramatic outcome for the patient. Therefore, it seems justified to evaluate new therapies that maintain or improve the visual function in these patients.

The Project includes a clinical trial whose purpose is the assessment of the safety of intravitreal administration of allogenic mesenchymal stem cells (MSC) in patients with NAION, a product in clinical research phase (PEI No. 15-007) already approved for other human clinical applications (PEI No. 15-007).

It can be considered that the therapy with intravitreal injection of MSC is a treatment option in patients with acute NAION, since through the paracrine properties of these cells (secretion of neurotrophic, immunomodulatory and anti-apoptotic factors) it may prevent or reduce the progression of axonal degeneration caused by this disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT03547206

Nonarteritic Anterior Ischemic Optic Neuropathy

TERMINATED PHASE2

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT02341560

Non Arteritic Anterior Ischemic Optic Neuropathy

TERMINATED PHASE2/PHASE3

Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

NCT02045212

Non-arteritic Ischemic Optic Neuropathy Optic Nerve Injuries

COMPLETED PHASE2

Visudyne® in Occult (VIO)

NCT00121407

Macular Degeneration

COMPLETED PHASE3

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085

Geographic Atrophy Macular Degeneration

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Arteritic Ischemic Optic Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mesenchymal stem from valladolid (MSV)

Allogenic mesenchymal stem cells from bone marrow

Group Type EXPERIMENTAL

intravitreal injection of MSV

Intervention Type PROCEDURE

A unique intravitreal injection of MSV in acute fase of NAION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intravitreal injection of MSV

A unique intravitreal injection of MSV in acute fase of NAION

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with acute unilateral NAION (within two weeks after the first symptoms) with at least two of the following:

1. Sudden and unpainful monocular vision loss
2. Visual field defects
3. Dyschromatopsia.
4. Ocular nerve head edema.
5. Afferent relative pupil defect.
* Patients ≥ 50 years old, able to freely give informed consent.
* Best corrected visual acuity (BCVA) ≤ 0,1 in study eye.
* Pseudophakia in study eye.
* Preserved pupil sphincter muscle motility
* Signed informed consent form before any study procedure.
* Signed data protection consent form before any study procedure.

Exclusion Criteria

* Giant cell arteritis evidence (clinical history, Erythrocyte sedimentation rate (ESR), C-Reactive Protein)
* Evidence of any other etiology that may justify the optic neuropathy (even in the non-study eye)
* History of systemic vasculitis, multiple sclerosis, collagenopathies or previous cancer treatments.
* Hypersensitivity or allergy to any compound used in the study, including investigational medicinal product (IMP).
* Positive pregnancy test at baseline
* Participation in any other research study within 2 months

* History of uveitis or active ocular inflammation
* History or evidence of glaucoma or high intraocular pressure ( ≥ 24 mmHg in either eye).
* Mean opacities or retinal pathologies in the study eye.
* Any previous vitreous or glaucoma surgery in the study eye
* Cataract surgery within 3 months in the study eye

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No